51 - 100 Employees
11 - 25 Engineers
$10M - $25M Funding
Series C

Data-driven and highly-targeted immunotherapies are the future of the fight against cancer. IsoPlexis (, develops novel solutions that are accelerating the revolution in immune and cell-based treatments of cancer. The IsoLight, a next-generation analytics platform, profiles responses at the single-cell level enabling researchers to generate a precise functional patient signature to help predict and understand complex response to cancer immunotherapies. IsoPlexis has partnered with leading biopharmaceutical companies and trial centers to generate real-world data to advance high-need areas of cell product characterization, immune biomarker discovery, and patient monitoring. IsoPlexis provides a strong level of customer focus. We pride ourselves with a high level of integrity, energy and sense of urgency to “make things happen”.

Engineering at ISOPLEXIS
Tech stack

Working at ISOPLEXIS
Free Food

Pizza Wednesdays and Happy Hour Fridays!

Company Retreats

Off site learning at Water's Edge Resort & Spa, Westbrook, CT

External Links

Interested in this company?
Skip straight to final-round interviews by applying through Triplebyte.